CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors
December 20, 2022 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative...
CVRx to Present at the Piper Sandler 34th Annual Healthcare Conference
November 16, 2022 08:00 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Launches new Barostim NEO2™ Implantable Pulse Generator
November 03, 2022 10:31 ET
|
CVRx, Inc.
The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. ...
CVRx to Attend Upcoming Investor Conferences
November 03, 2022 08:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Reports Third Quarter 2022 Financial and Operating Results
November 01, 2022 16:15 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call on November 1st, 2022
October 18, 2022 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 29, 2022 08:30 ET
|
CVRx, Inc.
MINNEAPOLIS, July 29, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Reports Second Quarter 2022 Financial and Operating Results
July 28, 2022 16:10 ET
|
CVRx, Inc.
MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
July 14, 2022 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Launches a new Barostim™ Programmer
July 12, 2022 08:30 ET
|
CVRx, Inc.
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has...